Naringenin Attenuates Diabetic Cardiac Injury via SIRT1 Activation in Streptozotocin‐Induced Rats
Cardiovascular Therapeutics · 2026
DOI: 10.1155/cdr/9581618 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Therapeutics, 2026. Verfasst von Baolan Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, The Fourth People's Hospital of Jinan Affiliated to Shandong Second Medical University, Jinan, China. Hauptthemen laut MEDLINE: Sirtuin 1, Diabetic Cardiomyopathies, Diabetes Mellitus, Experimental, Flavanones. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jinan Health Commission.
Abstract (Originalsprache)
Objective
Diabetic cardiomyopathy (DCM) lacks targeted therapies. This study investigated naringenin (NAR), a citrus flavonoid, in a streptozotocin (STZ)‐induced diabetic rat model with cardiac complications, focusing on SIRT1‐mediated mechanisms.
Methods
Rats ( n = 8/group) included control, NAR, DCM, DCM + NAR, and DCM + NAR + EX‐527 (SIRT1 inhibitor). After 8 weeks, metabolic profiles, cardiac function, histopathology, oxidative stress (Nuclear Factor Erythroid–Related Factor 2 [Nrf2], MDA, SOD, and GSH), inflammation (nuclear factor kappa B [NF‐ κ B], TNF‐ α , and IL‐6), apoptosis (Bax/Bcl‐2 and Caspase‐3), fibrosis (transforming growth factor beta [TGF‐ β ] and Smad2), and SIRT1 signaling were analyzed.
Results
NAR exhibited hypoglycemic effects, stimulated the release of insulin, and enhanced the lipid profile, thus maintaining the structural integrity of cardiomyocytes and preventing an increase in heart weight, while also restoring the histomorphology in DCM rats. Moreover, NAR influenced both systolic and diastolic blood pressure; reduced serum levels of CK‐MB, BNP, and troponin T; downregulated the activity of TGF‐ β , Smad2, and Caspase‐3; and decreased the Bax/Bcl‐2 ratio. Crucially, NAR upregulated SIRT1 and modulated the levels of Nrf2, NF‐ κ B, Smad2, and Forkhead Box Protein O1 (FOXO1) in the cardiac tissues of the DCM group. These findings were associated with a significant reduction in oxidative stress and inflammation, alongside diminished NF‐ κ B activity, while promoting Nrf2 activity and Bcl‐2. Importantly, the effects of NAR were counteracted by EX‐527.
Conclusion
NAR protects against DCM primarily through SIRT1 activation, integrating hypoglycemic, antioxidant, anti‐inflammatory, antifibrotic, and antiapoptotic actions. SIRT1 represents a promising target for flavonoid‐based DCM therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, The Fourth People's Hospital of Jinan Affiliated to Shandong Second Medical University, Jinan, China.
- Department of Biology, Science & Research Institute, Islamic Azad University, Tehran, Iran, tiau.ac.ir.
ORCID-Profile: Li Zhang
Förderung
- Jinan Health Commission
Zitieren
APA
Wang, B., Zhang, D., Zhang, F., Meng, X., Zhang, L., Li, Z., & Bostani, A. (2026). Naringenin Attenuates Diabetic Cardiac Injury via SIRT1 Activation in Streptozotocin‐Induced Rats. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/9581618
Vancouver
Wang B, Zhang D, Zhang F, Meng X, Zhang L, Li Z, et al. Naringenin Attenuates Diabetic Cardiac Injury via SIRT1 Activation in Streptozotocin‐Induced Rats. Cardiovascular Therapeutics. 2026. doi:10.1155/cdr/9581618
BibTeX
@article{Wang2026,
author = {Wang, Baolan and Zhang, Dandan and Zhang, Fudan and Meng, Xue and Zhang, Li and Li, Zhenzuo and Bostani, Amirabas},
title = {Naringenin Attenuates Diabetic Cardiac Injury via SIRT1 Activation in Streptozotocin‐Induced Rats},
journal = {Cardiovascular Therapeutics},
year = {2026},
doi = {10.1155/cdr/9581618}
}
EUVIMED